CRP

A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.

The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.

IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.

For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...

This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...

A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.

Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.

This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.

Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...

People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...

Diet is a potentially modifiable factor that could affect symptoms, inflammation, and the gut microbiome in ulcerative colitis; this trial aims to test whether a modified Mediterranean diet added to standard therapy...

Early, easily available blood markers that predict mucosal healing could help clinicians decide sooner whether a new or intensified therapy is working, potentially reducing prolonged ineffective treatment and guiding...

A multimodal, simpler activity score could improve practical disease monitoring when full ileocolonoscopy isn’t possible and help standardize treat-to-target practice across centers.

A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...

Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.

Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.

This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.

Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...

Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and CRP. The original article is from Journal of medical biochemistry.

A noninvasive, explainable model that combines CT enterography radiomics with CRP could make it easier to monitor mucosal healing in small‑bowel Crohn’s disease without repeated invasive enteroscopy, especially after...

A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.

A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...

People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...

If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.

The study connects a bothersome UC symptom (bowel urgency) to intestinal ultrasound signs of transmural inflammation, suggesting ultrasound might help explain and track symptom-related inflammation without relying solely...

Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...

Both EEN and the Crohn’s disease exclusion diet are used to induce remission in children with Crohn’s disease. Evidence that they perform similarly through 52 weeks may help families and clinicians choose the approach...

Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.

Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...

A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...

This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...

Diet quality was linked to gut microbiome features and exploratory differences in inflammatory markers and symptoms in adults with Crohn disease from Puerto Rico; understanding these links may help tailor dietary...

Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...

A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.

This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a...

The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.

Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...

People receiving immune checkpoint inhibitors who develop colitis may face different risks of needing stronger immunosuppression depending on the ICI drug class. Understanding which features predict escalation could...

The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.

This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...

Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...

People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...

Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...